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Introduction: The accumulation of amyloid-β is a pathological hallmark of Alzheimer’s
disease and is a target for molecular imaging probes to aid in diagnosis and disease
monitoring. This study evaluated the feasibility of using a radiolabeled monoclonal anti-
amyloid-β antibody (JRF/AβN/25) to non-invasively assess amyloid-β burden in aged
transgenic mice (APPPS1–21) with µPET imaging.
Methods: We investigated the antibody JRF/AβN/25 that binds to full-length Aβ.
JRF/AβN/25 was radiolabeled with a [89Zr]-desferal chelate and intravenously injected
into 12–13 month aged APPPS1–21 mice and their wild-type (WT) controls. Mice
underwent in vivo µPET imaging at 2, 4, and 7 days post injection and were sacrificed at
the end of each time point to assess brain penetrance, plaque labeling, biodistribution,
and tracer stability. To confirm imaging specificity we also evaluated brain uptake of
a non-amyloid targeting [89Zr]-labeled antibody (trastuzumab) as a negative control,
additionally we performed a competitive blocking study with non-radiolabeled Df-
Bz-JRF/AβN/25 and finally we assessed the possible confounding effects of blood
retention.
Results: Voxel-wise analysis of PET data demonstrated significant [89µ Zr]-Df-Bz-
JRF/AβN/25 retention in APPPS1–21 mice at all time points investigated. With ex vivo
measures of radioactivity, significantly higher retention of [89Zr]-Df-Bz-JRF/AβN/25 was
found at 4 and 7 days pi in APPPS1–21 mice. Despite the observed genotypic
differences, comparisons with immunohistochemistry revealed that in vivo plaque
labeling was low. Furthermore, pre-treatment with Df-Bz-JRF/AβN/25 only partially
blocked [89Zr]-Df-Bz-JRF/AβN/25 uptake indicative of a high contribution of non-
specific binding.
Frontiers in Aging Neuroscience | www.frontiersin.org 1 March 2016 | Volume 8 | Article 67
fnagi-08-00067 March 30, 2016 Time: 16:31 # 2
Waldron et al. Preclinical Antibody Imaging of Amyloid-β
Conclusion: Amyloid plaques were detected in vivo with a radiolabeled monoclonal
anti-amyloid antibody. The low brain penetrance of the antibody in addition to non-
specific binding prevented an accurate estimation of plaque burden. However, it should
be noted that [89Zr]-Df-Bz-JRF/AβN/25 nevertheless demonstrated in vivo binding and
strategies to increase brain penetrance would likely achieve better results.
Keywords: amyloid imaging, monoclonal antibody, 89Zirconium, small animal imaging, Alzheimer
INTRODUCTION
Alzheimer’s disease (AD) is a chronic neurodegenerative disease
and the leading cause of dementia in the elderly population. One
of its pathological hallmarks is the accumulation of extracellular
amyloid-β deposits, arising from the amyloidogenic processing of
amyloid precursor protein (APP) (Selkoe, 1991). The deposition
of amyloid-β is an early pathogenic event in AD, proposed to
initiate 20–30 years before clinical symptoms become manifest
(Bateman et al., 2012). The ability to detect and quantify
amyloid-β in vivo could thus facilitate early diagnosis and
monitoring of therapeutic responses to anti-amyloid agents
(Rowe and Villemagne, 2013). Based on this premise several
positron emission tomography (PET) radiotracers capable of
detecting amyloid-β have been developed. While amyloid
tracers such as [11C]-labeled Pittsburgh compound B ([11C]-
PiB) demonstrate increased retention from prodromal through
to late disease stages (Li et al., 2008; Rowe et al., 2010),
they recognize only fibrillar amyloid-β, thus neglecting a wide
diversity of biochemical and morphological amyloid-β subtypes.
Moreover non-specific accumulation of these tracers in white
matter (Fodero-Tavoletti et al., 2009) and amyloid-unrelated
regions has raised concerns over their purported specificity
(Kepe et al., 2012). The ability to image a wider spectrum
of amyloid-β subtypes would provide greater understanding of
the composition of plaques and the pharmacological effects of
amyloid-β targeted therapies. However, the specificity required
for this purpose is not achievable with small molecules and a
more viable approach would be the use of radiolabeled epitope
specific anti-amyloid antibodies.
With this objective in mind we previously evaluated a
radiolabeled monoclonal mouse antibody (mAb) directed against
amyloid-β for use as an in vivo imaging agent (Fissers et al.,
2016). JRF/AβN/25 is an N-terminal end-specific antibody
directed against the first seven amino acids of human Aβ1–
40/42 (Vandermeeren et al., 2001; Mathews et al., 2002) and
thus recognizes full length Aβ peptides. With the expected low
brain permeability of the antibody, the long-lived radioisotope
89Zr (T 1/2 = 78.41 h) was chosen as a suitable radiolabel that
would accommodate the long biological half-life of antibodies
and possible accumulation of antibody over time on its target.
In our previous work (Fissers et al., 2016), 89Zr was attached to
JRF/AβN/25 using the bifunctional chelator desferal. Using an
in vitro saturation assay we demonstrated a nanomolar affinity
(Kd = 0.85 nM) of [89Zr]-Df-Bz-JRF/AβN/25 against Aβ1–40 in
addition to low non-specific binding. Under in vitro conditions
autoradiographs showed binding of [89Zr]-Df-Bz-JRF/AβN/25
to amyloid-β plaques in the brain of an APPPS1–21 mouse.
Lastly, in vivo tests in healthy mice indicated tracer stability,
a favorable biodistribution and some modest brain penetrance
(Fissers et al., 2016). Given these promising results this study
aimed to investigate whether the radiolabeled antibody could
be used in conjunction with micro-PET (µPET) imaging to
quantify amyloid-β burden. We performed a cross-sectional
investigation of tracer uptake over a 7 days period in aged
transgenic APPPS1–21 and wild-type (WT) mice. To cross-
validate in vivo radioactivity measures, brain uptake was also
measured with γ-counting and autoradiography. As a gold
standard evaluation, plaques labeled in vivo were assessed with
immunohistochemistry and compared to total plaque load to
provide a measure of sensitivity. To assess tracer specificity
several additional experiments were conducted. These involved
a negative control study with the non-amyloid targeted [89Zr]-
trastuzumab antibody (Slamon et al., 2001), a competitive
blocking study and lastly a study to assess possible confounding
effects of blood radioactivity.
MATERIALS AND METHODS
Animals
An overview of the animals involved in each experiment and the
procedures performed are shown in Table 1. Female APPPS1–
21 mice and their littermate controls were received in kind
from Janssen Pharmaceutica (Beerse, Belgium). APPPS1–21
mice overexpress human mutant amyloid precursor protein
(hAPP695swe) and presenilin -1 (L166P) under the control of
the neuron specific Thy-1 promoter on a C57BL/6J background
and develop insoluble amyloid-β deposition in the cortex as of
6 weeks of age (Radde et al., 2006).
The animals were kept under environmentally controlled
conditions (12 h light/dark cycle, 20–24◦C and 40–70% relative
humidity) in individually ventilated cages with food and water ad
libitum. Animals were group-housed and received environmental
enrichment. The study protocol was approved by the local
Animal Experimental Ethical Committee of the University of
Antwerp, Belgium (2012–2025) where the in vivo experiments
were performed. All animal studies were ethically reviewed and
carried out in accordance with European Directive 86/609/EEC
Welfare and Treatment of Animals.
[89Zr]-Labeling of the Antibody and
Stability Measures
JRF/AβN/25 was radiolabeled with 89Zr using a desferal chelator
as described previously (Fissers et al., 2016). [89Zr]-trastuzumab
was received in kind from BV Cyclotron (Amsterdam, The
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TABLE 1 | Overview of study design.
Study Antibody Animals Age
(months)
Time point
(days pi)
Procedures
WT APPPS1–21 µPET ARG Biodistribution IHC Plasma
stability
Proof of concept [89Zr]-Df-Bz-JRF/AβN/25 18 18 12–13 2, 4,7
√ √ √ √ √
Negative control [89Zr]-trastuzumab 3 3 12–13 4
√ √ √ √
–
Blocking [89Zr]-Df-Bz-JRF/AβN/25 – 6 12–13 4
√ √ √ √
–
Blood contribution [89Zr]-Df-Bz-JRF/AβN/25 3 3 12–13 4 –
√
Brain only
√
–
Netherlands). Plasma was obtained from blood by centrifugation
and analyzed by SEC-HPLC and radio-iTLC for the presence
of radiometabolites as described previously (Fissers et al.,
2016).
In Vivo Imaging with µPET and Ex Vivo
Biodistribution
In the proof of concept, negative control, and blood contribution
studies (Table 1), mice received a lateral tail vein injection of
133 µg in maximum 200 µl volume of [89Zr]-Df-Bz-JRF/AβN/25
or [89Zr]-trastuzumab. In the blocking study mice were injected
with modified unlabeled Df-Bz-JRF/AβN/25 (400 µg in volume
of 100 µl) 2 h prior to receiving the radiolabeled mAb (volume of
150 µl). All µPET scans were static acquisitions. To account for
variation in injected dose and time difference between scanning,
the length of µPET acquisitions was determined on the basis
of equivalent count rates. Anesthesia was induced by inhalation
of 2% isoflurane (5% for induction, 2% for maintenance)
supplemented with oxygen. All µPET data was reconstructed as
described previously (Waldron A. et al., 2015).
Volume-of-interest (VOI) and voxel-wise analysis (statistical
parametric mapping) methods were performed on reconstructed
images using PMOD v3.3 (PMOD technologies, Switzerland) and
SPM8 (Wellcome Trust Centre, UK). Individual PET images were
spatially normalized into the space of a predefined mouse brain
template (Mirrione et al., 2007), masked to remove extracerebral
activity and then expressed in percent injected dose (tissue
uptake[kBq/cc]/ injected dose[kBq] ∗ 100). For VOI analysis,
images were subsequently co-registered with a predefined mouse
brain VOI template aligned with the aforementioned Mirrione
CT/MRI atlas and tracer uptake values were extracted for
each delineated VOI. With this approach regional values are
quantified as the average uptake over the total number of voxels
in a VOI. For voxel-wise analysis of tracer uptake between
genotypes a two-sample unpaired t-test was applied to images,
with a significance threshold of p < 0.01. To control for errors
at a reasonable level we additionally set an extent threshold
of 100 voxels (48 mm3). In this instance a voxel is only
considered active if it belongs to a cluster of 100 contiguous
active voxels. Quantification of this voxel-wise analysis was
investigated by calculating the number of significant voxels in a
VOI [CT/MRI template (Mirrione et al., 2007)] relative to the
total number of voxels (% sign) in that region. Images were
smoothed with a Gaussian filter (0.5 mm) for visualization and
are overlaid on a T2-weighted MRI template for anatomical
reference.
Subsequent to scanning, mice were kept under isoflurane
anesthesia and a cardiac puncture was performed to collect
blood. Thereafter mice were sacrificed by cervical dislocation
and all organs were removed, rinsed in buffer, and blotted
dry. The brain was hemisected with the left hemisphere snap
frozen in chilled 2-methyl-butane for autoradiography and the
right hemisphere fixed in formaldehyde. Radioactivity in the
samples was measured using an automatic γ-counter. The
uptake of radioactivity in blood, right brain hemisphere and
peripheral organs was expressed as percentage of the injected
dose per gram of tissue plus or minus the standard deviation
(%ID/g± SD).
In the blood contribution study mice were anesthetized with an
intraperitoneal injection of Nembutal (200 mg/kg) and perfused
transcardially with ice-cold 0.1 M phosphate buffer saline (PBS)
to remove blood. Thereafter brain tissue was processed as
described above.
Ex Vivo Validation by Autoradiography
and Immunohistochemistry
Sagittal brain slices (20 µm) were obtained through cryostat
sectioning (Leica) of the frozen left brain hemisphere. After
air-drying at 37◦C, the sections were co-exposed with a
14C standard on a phosphor imaging plate (Fujifilm BAS
IP MS 2025) for 72 h. Following exposure, plates were read
using a Fuji Phosphorimager system (FLA-700). Whole brain
slice radioactivity concentrations were calculated through
manual region of interest delineation (ImageJ). Radioactivity
concentration was quantified through interpolation of
measured values in a 14C standard curve (Van Eetveldt and
Dedeurwaerdere, under review) and then corrected for injected
dose and radioactive decay.
Immunohistochemistry was performed on slices from the
left hemisphere (fresh frozen) according to two protocols. The
objective of the first protocol was to assess in vivo antigen
labeling, in this way the injected [89Zr]-labeled antibody acted
as a primary antibody. Brain slices were thus incubated with
only secondary antibody to stain areas in which injected antibody
had bound. In the second protocol total plaque load was stained
for by applying exogenous primary antibody on brain slices
and then with secondary antibody as above. Comparison of
the results obtained with these protocols allowed the amount
of antigen captured through in vivo uptake relative to the
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true amount of antigen available to be determined. Staining
was performed on a Ventana Discovery autostainer using a
chromomap detection kit. Briefly sections were rinsed in wash
buffer then incubated in primary antibody diluted in PBS
(JRF/AβN/25, 1/500) at 37◦C for 28 min. Sections were rinsed
again in wash buffer and then fixed in NBF (neutral buffered
formalin) for 4 min. Secondary anti-mouse antibody conjugated
to HRP (1/50 dilution in PBS) was applied for 28 min and DAB
was used as a chromogen for visualization of the staining. Finally
sections were counterstained with hematoxylin, mounted, and
coverslipped.
Brain tissue from the right brain hemisphere of a subset
of animals at 4 days pi also underwent staining for total
plaque load. This tissue was preferentially used for quantification
due to reduced non-specific background obtained with this
protocol. After γ-counting, brain tissue was fixed, paraffin-
embedded, and cut into 5-µm coronal sections. De-waxed
and rehydrated sections underwent tissue depigmentation in
potassium permanganate, oxalic acid and water and were
subsequently pretreated with 70% formic acid for 10 min for
epitope retrieval. Endogenous peroxidase activity was blocked
by rinsing in 3% hydrogen peroxide for 5 min. Thereafter,
sections were incubated with mouse anti-amyloid primary
antibody (JRF/AβN/25 1:10,000 1 h) and processed as described
above. Virtual images were acquired using a Mirax Digital
Slide Scanner (Zeiss), and image analysis was performed
using the Definiens analysis software package v1.5. Regions
of interests (ROIs) were manually delineated in accordance
with Franklin and Paxinos atlas (Franklin and Paxinos, 1997),
and for each ROI, the percentage of DAB-labeled area was
calculated.
RESULTS
[89Zr]-Df-Bz-JRF/AβN/25 Demonstrates
Stable Pharmacokinetics In Vivo
The average uptake of [89Zr]-Df-Bz-JRF/AβN/25 in APPPS1–
21 and WT mice in selected organs are shown in Table 2.
There were high circulating levels of [89Zr]-Df-Bz-JRF/AβN/25
present in blood at 2 days pi with 9.36 ± 1.38%ID/g in
APPPS1–21 mice and 8.41 ± 2.23%ID/g in WT. Blood activity
gradually decreased to 4.62 ± 1.76%ID/g and 5.08 ± 1.11%ID/g
at 7 days pi, respectively. Liver uptake was high at all time
points investigated and is indicative of hepatobiliary clearance.
There was a notable accumulation of radioactivity in skull bone
with highest levels of uptake at 7 days pi, 5.84 ± 3.19%ID/g
in APPPS1–21 and 6.43 ± 1.76%ID/g in WT. Plasma stability
of [89Zr]-Df-Bz-JRF/AβN/25 was high at all time points as
measured by both HPLC and iTLC, with the latter method
generally showing higher values. By 7 days pi levels of intact
[89Zr]-Df- Bz-JRF/AβN/25 were 96.37 ± 1.76% in WT and
94.73 ± 1.28% in APPPS1–21 plasma, respectively, as quantified
by iTLC. Stability results from earlier time points and from HPLC
measures can be found in Supplementary Table S1.
Transgenic Mice Demonstrate Increased
Brain Uptake of [89Zr]-Df-Bz-JRF/AβN/25
Figure 1 displays the results from VOI analysis of the PET
imaging. We used unpaired Student’s t-tests (corrected for
multiple comparisons) to compare [89Zr]-Df-Bz-JRF/AβN/25
retention between brain regions with this analysis. At 2 days
pi no clear differences were observed between WT and
APPPS1–21 mice (Figure 1A). At 4 days pi, APPPS1–21 mice
demonstrated increased [89Zr]-Df-Bz-JRF/AβN/25 retention in
all brain regions investigated (Figure 1B). The most significant
differences were found in the brain stem (p = 0.00015) followed
by the midbrain (p = 0.0015) and thalamus (p = 0.0045). By
7 days pi significant differences remained only in the brain
stem (p = 0.0021) and amygdala (p = 0.000057) (Figure 1C).
With a more sensitive voxel-wise analysis (Figure 2A), significant
differences in [89Zr]-Df-Bz-JRF/AβN/25 retention between
genotypes was observed already at 2 days pi in the midbrain
(16.3%) and brain stem (13%). By 4 days pi, significant voxels
increased substantially in the brain stem (89%), midbrain
(79.3%), amygdala (58.7%), hypothalamus (44.7%), and basal
forebrain and septum (44%). While the percent of significant
voxels in the whole brain remained relatively constant between 4
and 7 days pi (32.1 and 29.6%, respectively), regionally there were
less significant voxels in the basal forebrain and septum (from
44% to 1.5%) and hypothalamus (44.7 to 1%) and an increase
in the cerebellum (from 35.4 to 51.3%). Figure 2B illustrates
the localization of significant voxels on an anatomical brain
template.
Subsequent to µPET scanning, brain radioactivity was
measured ex vivo by γ-counting. Figure 2C shows the brain
uptake values of [89Zr]-Df-Bz-JRF/AβN/25 in both WT and
TABLE 2 | Selected ex vivo biodistribution data of [89Zr]-Df- Bz-JRF/AβN/25 at different time points after intravenous injection in APPPS1–21 and WT
mice.
Genotype Time (d) Blood Heart Lungs Liver Spleen Kidneys Muscle Skull bone
APPPS1–21 2 9.36 ± 1.38 2.55 ± 0.46 3.72 ± 0.63 6.91 ± 1.92 6.18 ± 1.53 3.93 ± 0.52 0.52 ± 0.15 3.92 ± 3.09
4 7.19 ± 1.3 2.17 ± 0.41 4.04 ± 1.12 8.29 ± 1.67 6.76 ± 0.73 3.9 ± 0.46 0.44 ± 0.09 3.4 ± 0.94
7 4.62 ± 1.76 1.37 ± 0.49 2.17 ± 0.73 6.88 ± 1.22 7.07 ± 2.91 2.59 ± 0.73 0.43 ± 0.13 5.84 ± 3.19
WT 2 8.41 ± 2.23 2.43 ± 0.67 3.19 ± 0.96 5.27 ± 0.96 4.82 ± 1.25 3.59 ± 1.12 0.51 ± 0.19 5.23 ± 2.69
4 7.94 ± 1.65 2.07 ± 0.35 3.59 ± 0.57 8.15 ± 1.66 6.89 ± 1.74 3.51 ± 0.3 0.45 ± 0.08 4.78 ± 2.74
7 5.08 ± 1.11 1.6 ± 0.34 2.5 ± 0.46 10.63 ± 2.44 8.21 ± 2.38 2.94 ± 0.35 0.37 ± 0.09 6.43 ± 1.76
Data is represented as the average percent of injected activity per gram tissue ± SD.
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FIGURE 1 | µPET imaging demonstrates increased brain uptake of [89Zr]-Df-Bz-JRF/AβN/25 in APPPS1–21 mice in comparison to WT. Mice were
injected with 133 µg of [89Zr]-Df-Bz-JRF/AβN/25 and brain uptake was measured by µPET scanning and quantified as the %ID/g. The graphs show the VOI analysis
of [89Zr]-Df-Bz-JRF/AβN/25 retention in WT and APPPS1–21 mice at (A) 2 days pi, (B) 4 days pi, and (C) 7 days pi. Significant genotype differences in retention
were observed at 4 and 7 days pi. Data is presented as mean + SD. Student’s t-test, ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05.
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FIGURE 2 | Voxel-wise analysis of the µPET data and ex vivo examination of brain tissue confirms higher accumulation of [89Zr]-Df-Bz-JRF/AβN/25
in APPPS1–21 mice. Graph (A) shows voxel-wise analysis, data is presented as the percent of each brain region that was significantly changed (increase). This
data is illustrated in image (B), the statistical T-maps represent areas of significant increases. After imaging mice were sacrificed and brain radioactivity was
measured ex vivo by (C) γ–counting and (D) autoradiography. Data is presented as the average + SD. (E) Representative autoradiograph of
[89Zr]-Df-Bz-JRF/AβN/25 uptake at 4 days pi in an APPPS1–21 mouse. Student’s t-test ∗∗∗∗p < 0.0001, ∗∗p < 0.01.
APPPS1–21 mice for all time points as measured by γ-counting.
With this method APPPS1–21 mice demonstrated a progressive
uptake of [89Zr]-Df-Bz-JRF/AβN/25, reaching peak uptake values
at 7 days pi (0.51 ± 0.16%ID/g). Retention in WT remained
constant over time. Using a 2-way ANOVA with genotype
and time as co-factors a significant effect was found for both
factors for [89Zr]-Df-Bz-JRF/AβN/25 uptake [F(1,29) = 32.68,
p < 0.0001 for genotype and F(2,29) = 8.183, p = 0.0015 for
uptake time]. Using unpaired Student’s t-tests (corrected for
multiple comparisons) between WT and APPPS1–21 uptake
at each time point, significantly higher retention of [89Zr]-
Df-Bz-JRF/AβN/25 was found at 4 (p < 0.01) and 7 days
pi (p < 0.0001). With ex vivo autoradiography a significant
genotype effect only was observed for [89Zr]-Df-JRF/AβN/25
retention [F(1,24) = 20.73, p < 0.0001]. In contrast to the trend
observed with γ-counting, uptake of [89Zr]-Df-JRF/AβN/25 was
highest at 4 days pi (0.014 ± 0.003%ID/ml) (Figure 2D).
Retention of [89Zr]-Df-JRF/AβN/25 in APPPS1–21 mice was
significantly higher than in WT at 4 and 7 days pi (both
p < 0.01). Localization of cerebral radioactivity at 4 days pi in
APPPS1–21 mice is shown by a representative autoradiogram in
Figure 2E.
[89Zr]-Df-Bz-JRF/AβN/25 Labels Plaques
to a Low Extent after i.v Injection
The entry of [89Zr]-labeled antibodies into the brain was
further evaluated ex vivo by immunostaining fresh-frozen brain
sections with secondary antibody (Figure 3). APPPS1–21 mice
displayed plaque-staining arising from the i.v injections
of [89Zr]-Df-Bz-JRF/AβN/25 (Figures 3G–I). However,
immunostained plaques were sparse and predominantly
located in the hippocampal region, the mammillary nucleus and
the pons. Adjacent brain sections were analyzed for total antigen
by exogenous addition of primary antibody and subsequent
standard immunohistochemical procedures. This analysis
revealed widespread plaque load (Figures 3J–L). Plaques were
not observed in WT mice (Figures 3A–F). We quantified plaque
load in the cortex, hippocampus, and brain stem of a subset
of animals (three TG and three WT) at 4 days pi using fixed
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FIGURE 3 | Immunohistochemistry demonstrates that [89Zr]-Df-Bz-JRF/AβN/25 labels plaques to a low extent after i.v injection. Sagittal brain slices
(20 µm) were cut and the sections were stained for amyloid-β. Images (A–C,G–I) represent in vivo labeling arising from i.v injections of [89Zr]-Df-Bz-JRF/AβN/25 and
are compared to adjacent slices that were stained for total plaque load (D–F,J–L). (Scale bar = 100 µm). Graph (M) depicts quantification of amyloid-β staining in
the cortex, hippocampus and brain stem. Data is shown as the mean + SD.
tissue from the right hemisphere. The cortex and hippocampus
demonstrated plaque load (4.95± 0.5% and 3.18± 0.35% marker
stain, respectively) while plaque staining was minimal in the
brain stem (0.83± 0.08% marker stain) (Figure 3M).
The Effects of Increased Blood–Brain
Barrier Permeability and Blood Retention
of [89Zr]-Df-Bz-JRF/AβN/25 are
Insignificant in APPPS1–21 Mice
Cerebral uptake of a non-amyloid targeted [89Zr]-labeled
antibody was investigated as a negative control. No significant
differences in cerebral [89Zr]-trastuzumab retention between
genotypes were observed with any of the employed methods
(Figures 4A–C). In comparison to cerebral retention of
[89Zr]-Df-Bz-JRF/AβN/25 in APPPS1–21 mice, [89Zr]-
trastuzumab retention was 1.8 times lower (Supplementary
Table S4). Blood and peripheral organ retention of [89Zr]-
trastuzumab was, however, similar to that demonstrated
for [89Zr]-Df-Bz-JRF/AβN/25 at 4 days pi (Supplementary
Table S2).
To further investigate the in vivo specificity of [89Zr]-
Df-Bz-JRF/AβN/25 we assessed the contribution of cerebral
blood to the measurements of brain [89Zr]-Df-Bz-JRF/AβN/25
retention. After tissue perfusion, brain retention of [89Zr]-
Df-Bz-JRF/AβN/25 significantly decreased (p = 0.0238) by
66% in WT mice and non-significantly decreased by 11% in
APPPS1–21 mice (Figure 4D) as measured by γ-counting.
Autoradiography demonstrated a similar trend with WT showing
a reduction of 67% (p = 0.0238) and APPPS1–21 demonstrating
a non-significant decrease of 27% (p = 0.1736) (Figure 4E).
Immunohistochemistry confirmed that plaques in perfused
APPPS1–21 mice were visible in the same brain regions as for
non-perfused mice.
Increased Brain Retention of
[89Zr]-Df-Bz-JRF/AβN/25 is Mediated in
Part by Non-specific Effects in
APPPS1–21 Mice
Lastly, we conducted a competitive blocking study (Figure 5).
Pre-administration of 400 µg unlabeled Df-Bz-JRF/AβN/25 to
APPPS1–21 mice did not alter blood or organ retention of [89Zr]-
Df-Bz-JRF/AβN/25 (Supplementary Table S3). VOI analysis of
the µPET imaging data showed significantly reduced [89Zr]-
Df-Bz-JRF/AβN/25 retention in pre-treated APPPS1–21 mice in
the brain stem (p = 0.0008), hypothalamus (p = 0.0023), and
amygdala (0.0048), when compared to un-treated APPPS1–21
at the same 4 days pi time point (Figure 5A). With voxel-wise
analysis we similarly showed the greatest significant decreases
between pre-treated and untreated APPPS1–21 mice in these
regions and additionally demonstrated appreciable differences in
the cerebellum (23.5%) and midbrain (20.8%) (Figures 5B,C).
With ex vivo measures, pre-treatment non-significantly reduced
brain retention in APPPS1–21 mice by 18 and 3.17% as measured
by γ-counting and autoradiography, respectively, (Figures 5D,E).
Immunohistochemistry confirmed the same regional pattern of
staining for mice with or without pre-treatment.
DISCUSSION
This study aimed to investigate the potential of a radiolabeled
monoclonal anti-amyloid-β antibody as an in vivo imaging agent.
[89Zr]-Df-Bz-JRF/AβN/25 demonstrated brain penetrance after
intravenous injection and showed significantly higher retention
in APPPS1–21 mice in comparison to their WT littermates.
Despite these increases, immunohistochemistry revealed sparse
plaque labeling that was confined to a limited number of brain
regions in APPPS1–21 mice. Furthermore plaque staining was
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FIGURE 4 | APPPS1–21 mice did not exhibit significant uptake of a non-amyloid targeted antibody in comparison to WT mice. Mice received an i.v
injection of 133 µg of [89Zr]-trastuzumab and were underwent µPET scanning at 4 days pi. Graph (A) depicts VOI analysis of [89Zr]-trastuzumab retention in WT and
APPPS1–21 mice, data is presented as mean + SD. After scanning, mice were sacrificed and brain radioactivity of [89Zr]-trastuzumab was measured by (B)
γ–counting and (C) autoradiography. No significant differences in cerebral [89Zr]-trastuzumab retention between genotypes were observed with either in vivo or ex
vivo methods. We compared brain retention of [89Zr]-Df-Bz-JRF/AβN/25 in APPPS1–21 with and without transcardial perfusion by (D) γ–counting and (E)
autoradiography, data is presented as mean + SD. Student’s t-test ∗p < 0.05. Retention of [89Zr]-Df-Bz-JRF/AβN/25 was significantly reduced in perfused WT but
not perfused APPPS1–21 mice.
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FIGURE 5 | Pre-treatment with non-labeled Df-Bz-JRF/AβN/25 only partially blocks [89Zr]-Df-Bz-JRF/AβN/25 uptake in APPPS1–21 mice. APPPS1–21
mice were treated with 400 µg of non-labeled Df-Bz-JRF/AβN/25 2 h prior to injection of [89Zr]-Df-Bz-JRF/AβN/25. Brain retention was assessed at 4 days pi.
Graph (A) depicts VOI analysis of the µPET imaging, data is presented as mean + SD. Graph (B) shows voxel-wise analysis, data is presented as the % of each
brain region that was significantly changed (decrease). Image (C) is statistical T-maps depicting regions of significantly reduced tracer retention in pre-treated versus
untreated APPPS1–21 mice. Radioactivity was measured ex vivo by (D) γ–counting and (E) autoradiography. Data is presented as the average ± SD. Student’s
t-test, ∗∗∗p < 0.001, ∗∗p < 0.01.
not confirmed in all regions that demonstrated increased in vivo
retention with µPET imaging which we attribute to possible
non-specific binding of the mAb in addition to the resolution
limitations of µPET imaging. The low brain penetrance and non-
specific binding of the mAb results in a low signal to noise ratio
and prevents an accurate estimation of total amyloid-β load thus
precluding its use as a biomarker with the current methods.
The entry of full-length antibodies across the blood–brain
barrier is known to be low and has been previously estimated
as 0.11% of the injected dose (Banks et al., 2002). High blood
concentrations and long systemic circulation can promote greater
uptake (Misra et al., 2003). Our previous study demonstrated
high blood radioactivity of [89Zr]-Df-Bz-JRF/AβN/25 until 2 days
pi (Fissers et al., 2016) and by prolonging the uptake time to
7 days we aimed at enhancing specific accumulation of the
antibody in plaque rich brain areas and additionally allow non-
specific wash-out of the tracer. Blood levels of [89Zr]-Df-Bz-
JRF/AβN/25 indeed remained relatively high up to 7 days pi
and as anticipated the tracer demonstrated the most significant
uptake in brain at later time points due to the better contrast
provided by a higher retention in transgenic mice and a lower
retention in WT. Using a [125I]-labeled antibody directed against
Aβ protofibrils, Magnusson et al previously demonstrated the
highest tracer retention in transgenic mice at 3 days pi in
comparison to earlier 1 day and 3 h time points (Magnusson
et al., 2013). However, even at the later time points investigated
here, levels of brain retention were still too low in terms of that
expected for useful radiotracers. While a brain uptake of 1%ID/g
of the 6E10 anti-amyloid antibody in transgenic mice has been
previously reported (McLean et al., 2012b), lower uptake values
similar to those demonstrated here are more prevalent (Banks
et al., 2002; Magnusson et al., 2013). Whether brain uptake
of [89Zr]-Df-Bz-JRF/AβN/25 would continue to increase as a
function of time is unknown. However, possible reductions in
tracer stability and radioactivity levels (and thus image quality)
over time would negate any benefits of further brain uptake.
While the long half-life of 89Zr allowed for prolonged uptake and
imaging, our biodistribution studies revealed high bone uptake.
Metabolism resulting in dissociation of the [89Zr]-desferal chelate
from the antibody and complete release of the 89Zr cation
is the likely cause of this radioactivity. Although the plasma
stability studies demonstrated a high percent of intact tracer and
minimal free 89Zr, this may be an inaccurate estimation as free
89Zr is avidly sequestered by bone thus removing it from the
circulation. Such high bone uptake with 89Zr-labeled antibodies
has been previously reported in rodents with biodistribution
studies showing up to 10% ID/g activity. Given the low spatial
resolution of µPET scanners and the small size of the mouse
brain the effect of spillover from skull bone radioactivity on
the accurate quantification of cerebral uptake is a pressing
issue for sensitivity. In terms of translational relevance, these
mechanisms are of less importance to human imaging studies
where metabolism of the [89Zr]-desferal chelate is considerably
less extensive.
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Given the low tracer amounts, [89Zr]-Df-Bz-JRF/AβN/25
could not accurately quantify total amyloid-β burden and
yielded an in vivo cerebral retention pattern which did not
correspond entirely to regions with known high plaque
load. Immunohistochemistry for in vivo plaque labeling
revealed targeting of [89Zr]-Df-Bz-JRF/AβN/25 mainly to the
hippocampus and pons with minimal plaque labeling observed
in frontal brain regions, areas in which the highest plaque load
is present (Radde et al., 2006; Waldron A.-M. et al., 2015).
This discrepancy can be seen when comparing the µPET
data at 4 days pi (Figure 1B) to the immunohistochemistry
quantification at the same time point (Figure 3M). From the
imaging data, the brain stem has significantly higher uptake
of [89Zr]-Df-Bz-JRF/AβN/25 than WT and a high uptake in
comparison to other brain regions such as the cortex and
hippocampus in the TG mice. However, ex vivo quantification of
plaque load demonstrated minimal plaque load in the brain stem
and a relatively high plaque load in the cortex and hippocampus.
With the high abundance of antigen available in these aged
APPPS1–21 mice it is likely that the low amounts of radiolabeled
antibody become rapidly sequestered near their point of entry.
In addition to this effect, the large size of the antibody may also
hinder diffusion within the parenchyma (McLean et al., 2012a).
Thus given the localization of staining and radioactivity around
the third and fourth ventricles we hypothesize entry of the
antibody through circumventricular regions. Magnusson et al.
(2013) similarly noted localization of an anti-amyloid antibody
to the ventricles, specifically the choroid plexus. The mechanisms
accounting for brain uptake are unknown and could not be
delineated by our current methods.
The cerebral levels of radioactivity in APPPS1–21 mice
appear to overestimate specific mAb retention when compared
with the low amount of plaque labeling observed with
immunohistochemistry. To probe possible non-specific effects we
conducted a number of further experiments. There is evidence to
suggest that the BBB is deficient in AD patients and transgenic
AD mouse models and that this alteration may allow antibodies
to infiltrate the brain (Kumar-Singh et al., 2005; Erickson and
Banks, 2013). While this factor may be necessary for brain
antibody imaging it is also a potential confound whereby an
enhanced BBB permeability in APPPS1–21 mice versus WT mice
would result in higher tracer retention unrelated to amyloid-
binding. To investigate such a mechanism we performed a
negative control study with [89Zr]-trastuzumab, a humanized
monoclonal antibody targeted against the herceptin receptor
(Slamon et al., 2001). In comparison to WT, APPPS1–21 mice
demonstrated non-significantly increased retention of [89Zr]-
trastuzumab with both in vivo and ex vivo techniques suggesting
a very modest influence of BBB integrity on mAb uptake in
APPPS1–21 mice.
[89Zr]-Df-Bz-JRF/AβN/25 is not plaque-specific and can
additionally bind to soluble amyloid-β present in blood and brain.
To investigate the contribution of blood-bound [89Zr]-Df-Bz-
JRF/AβN/25 we measured cerebral radioactivity after removal of
the blood fraction through transcardial perfusion. By comparing
to the previously investigated [89Zr]-Df-Bz-JRF/AβN/25 cohort
we found brain radioactivity to be reduced by 11–27% in
APPPS1–21 and 66–67% in WT after perfusion. Thus while
blood retention may account for some of the radioactivity
signal, it appears that tissue retention is the predominant
source in APPPS1–21 mice. This tissue source encompasses both
specific binding to plaques in addition to non-specific binding.
To assess non-specific tissue binding a competitive blocking
study with non-labeled Df-Bz-JRF/AβN/25 was performed. With
this we demonstrated that cerebral retention of [89Zr]-Df-Bz-
JRF/AβN/25 could be blocked to a maximum of 18% in APPPS1–
21 mice, independent of changes in peripheral biodistribution.
This modest reduction points to a possible contribution of non-
specific tissue binding of [89Zr]-Df-Bz-JRF/AβN/25. However,
incomplete blocking may also have resulted from the short uptake
period (2 h) of the non-labeled antibody. It should be noted
that the decreased uptake after pre-treatment was not confirmed
by autoradiography. The main disadvantage with this technique
is the requirement for brain sectioning into 2D sections which
naturally results in the loss of 3D spatial consistency of the
brain. In this study we analyzed triplicate sagittal brain sections
(20 µm thick) for a representative sampling of brain radioactivity
levels. The small volume analyzed contrasts with the whole 3D
volumes measured by uPET imaging and likely accounts for
the discrepancy between measurements and the apparent lower
sensitivity.
A number of methods to circumvent the BBB have been
employed to deliver antibodies to the brain and such techniques
would likely improve the plaque detecting abilities of [89Zr]-Df-
Bz-JRF/AβN/25. Disruption of the BBB by focused ultrasound
(Jordão et al., 2010) or hyperosmotic solutions (McLean et al.,
2012b) have shown increased targeting of antibodies to the
brain. While these methods are valuable for proof-of-concept,
mechanical and chemical BBB disruption are not clinically
translatable. More viable methods have focused on antibody
engineering to produce fragments of lower molecular weight
(Poduslo et al., 2007) in addition to biochemical modification
with polymers to enhance brain permeability (Poduslo et al.,
2007; McLean et al., 2012b). Alternatively, receptor-mediated
transcytosis approaches that exploit the insulin-like growth factor
and transferrin receptors (Bien-Ly et al., 2011) could be employed
to increase brain targeting.
CONCLUSION
In conclusion, the current results suggest limited utility of
[89Zr]-Df-Bz-JRF/AβN/25 as amyloid imaging agent with the
current methods. However, it should be noted that [89Zr]-Df-Bz-
JRF/AβN/25 nevertheless demonstrated in vivo plaque binding
and strategies to increase brain penetrance would likely achieve
better results.
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